Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Latest Information Update: 26 Jul 2021
At a glance
- Drugs Antroquinonol (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Golden Biotechnology Corporation
Most Recent Events
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.
- 26 Nov 2020 Results published in the Golden Biotechnology Corporation Media Release.